{"title":"Current challenges in the management of follicular lymphoma.","authors":"Maryam Sarraf Yazdy, Chaitra Ujjani","doi":"10.2217/ijh-2017-0003","DOIUrl":null,"url":null,"abstract":"<p><p>Although typically indolent in nature, follicular lymphoma remains an ongoing challenge for practicing oncologists. While response rates >90% can be achieved with rituximab-based chemoimmunotherapy in advanced stage patients, the complete remission rates are substantially lower and patients inevitably relapse. The inability to achieve a complete remission and an early progression of disease have recently been determined to be indicative of poorer long-term outcomes. A greater understanding of the pathogenesis of follicular lymphoma has enabled the development of targeted therapies, which may improve standard treatment approaches. Examples include lenalidomide and obinutuzumab, which are currently in front-line Phase III investigation. Other therapies of interest include small molecule inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171972/pdf/ijh-06-13.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ijh-2017-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/6/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Although typically indolent in nature, follicular lymphoma remains an ongoing challenge for practicing oncologists. While response rates >90% can be achieved with rituximab-based chemoimmunotherapy in advanced stage patients, the complete remission rates are substantially lower and patients inevitably relapse. The inability to achieve a complete remission and an early progression of disease have recently been determined to be indicative of poorer long-term outcomes. A greater understanding of the pathogenesis of follicular lymphoma has enabled the development of targeted therapies, which may improve standard treatment approaches. Examples include lenalidomide and obinutuzumab, which are currently in front-line Phase III investigation. Other therapies of interest include small molecule inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells.
滤泡性淋巴瘤是一种典型的懒散性淋巴瘤,但对于肿瘤医生来说,它仍然是一项持续的挑战。虽然晚期患者使用利妥昔单抗化疗免疫疗法可获得大于90%的应答率,但完全缓解率却低得多,而且患者不可避免地会复发。无法实现完全缓解和疾病早期进展最近被确定为长期疗效较差的指标。随着人们对滤泡性淋巴瘤发病机理的进一步了解,靶向疗法得以开发,这可能会改善标准治疗方法。例如来那度胺和奥比奴珠单抗,这两种药物目前正处于前线III期研究阶段。其他值得关注的疗法包括小分子抑制剂、免疫检查点抑制剂和嵌合抗原受体 T 细胞。
期刊介绍:
International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.